🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GSK573719

Found 114 matching trials

Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment

PHASE1

This study will assess the safety and pharmacokinetics of inhaled GSK573719...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-03-29

Trial ID

NCT01571999

Treatments Being Tested

Inhaled GSK573719 Inhaled GSK573719/vilanterol

Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

Batefenterol is a novel bifunctional molecule that combines muscarinic anta...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-11-06

Trial ID

NCT02570165

Treatments Being Tested

Batefenterol Umeclidinium/ Vilanterol Placebo

To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)

PHASE1

This will be a randomized, double-blind, single-dose, three-period balanced...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-11-08

Trial ID

NCT01725685

Treatments Being Tested

FF 400 mcg UMEC 500 mcg FF/UMEC 400/500 mcg

A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

PHASE2

This study will evaluate the efficacy and safety data of AZD8871 in patient...

Status

Completed

Location

Research Site

Start Date

2018-10-10

Trial ID

NCT03645434

Treatments Being Tested

AZD8871 Anoro® Ellipta®

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

PHASE3

The primary objective is to compare the efficacy of UMEC/VI Inhalation Powd...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-09-15

Trial ID

NCT01899742

Treatments Being Tested

Umeclidinium/Vilanterol 62.5/25 mcg Tiotropium 18 mcg

Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg

PHASE3

The purpose of this study is to evaluate the lung function response to UMEC...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-10

Trial ID

NCT01716520

Treatments Being Tested

Umeclidinium/Vilanterol 62.5/25 mcg Umeclidinium 62.5 mcg Vilanterol 25 mcg

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

PHASE1

This study will evaluate the pharmacokinetics of FF, UMEC and VI administer...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-07-15

Trial ID

NCT01894386

Treatments Being Tested

FF 400 mcg UMEC 500 mcg UMEC 250 mcg VI 100 mcg

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

PHASE4

The goal of this clinical trial is to determine if triple inhaled therapy w...

Status

Completed

Location

Narongkorn Saiphoklang

Start Date

2025-04-01

Trial ID

NCT06905483

Treatments Being Tested

Budesonide/Glycopyrronium/Formoterol (BGF)Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This study is a 12-week, multicenter, randomized, double blind, parallel gr...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-09-01

Trial ID

NCT02152605

Treatments Being Tested

UMEC/VI Placebo

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

Previous Next